The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Open accessAbstract
BACKGROUND: Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment for metastatic colorectal cancer. We evaluated capecitabine in the adjuvant setting. METHODS: We randomly assigned a total of 1987 patients with resected stage III colon cancer to receive either oral capecitabine (1004 patients) or bolus fluorouracil plus leucovorin (Mayo Clinic regimen; 983 patients) over a period of 24 weeks. The primary efficacy end point was at least equivalence in disease-free survival; the primary safety end point was the incidence of grade 3 or 4 toxic effects due to fluoropyrimidines. RESULTS: Disease-free survival in the capecitabine group was at least equivalent to that in the fluorouracil-plus-leucovorin group (in the intention-to-treat analysis, P<0.001 for the comparison of the upper limit of the hazard ratio with the noninferiority margin of 1.20). Capecitabine improved relapse-free survival (hazard ratio, 0.86; 95 percent confidence interval, 0.74 to 0.99; P=0.04) and was associated with significantly fewer adverse events than fluorouracil plus leucovorin (P<0.001). CONCLUSIONS: Oral capecitabine is an effective alternative to intravenous fluorouracil plus leucovorin in the adjuvant treatment of colon cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Stewart, B. W., & Kleihues, P. (2003) · Cited by 2,386
Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J., McAllister, P., Van Cutsem, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.063 · Cited by 1,430
Self-citationMiwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
(1995) · The Lancet · doi:10.1016/s0140-6736(95)90696-7 · Cited by 1,066
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-5-199503010-00001 · Cited by 925
Patient preferences for oral versus intravenous palliative chemotherapy.
Liu, G., Franssen, E., Fitch, M. I., & Warner, E. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.110 · Cited by 919
Edwards, B. K., Howe, H. L., Ries, L. A. G., Thun, M. J., Rosenberg, H. M., Yancik, R., Wingo, P. A., Jemal, A., & Feigal, E. G. (2002) · Cancer · doi:10.1002/cncr.10593 · Cited by 880
O'Connell, M. J., Mailliard, J. A., Kahn, M. J., Macdonald, J. S., Haller, D. G., Mayer, R. J., & Wieand, H. S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.246 · Cited by 585
Sch�ller, J., Cassidy, J., Dumont, E., Roos, B., Banken, L., Mori, K., Reigner, B., Utoh, M., Weidekamm, E., & Durston, S. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050043 · Cited by 534
Self-citationWolmark, N., Rockette, H., Mamounas, E., Jones, J., Wieand, S., Wickerham, D. L., Bear, H. D., Atkins, J. N., Dimitrov, N. V., Glass, A. G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3553 · Cited by 493
Cassidy, J., Twelves, C., Van Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., Bugat, R., Burger, U., Garin, A., Graeven, U., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf089 · Cited by 425
Self-citationCutsem, E. V., Hoff, P. M., Harper, P., Bukowski, R. M., Cunningham, D., Dufour, P., Graeven, U., Lokich, J., Madajewicz, S., Maroun, J. A., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601676 · Cited by 401
Self-citationBorner, M. M., Schöffski, P., de Wit, R., Caponigro, F., Comella, G., Sulkes, A., Greim, G., Peters, G. J., van der Born, K., Wanders, J., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00371-9 · Cited by 316
Ayanian, J. Z., Zaslavsky, A. M., Fuchs, C. S., Guadagnoli, E., Creech, C. M., Cress, R. D., O’Connor, L. C., West, D. W., Allen, M. E., Wolf, R. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.178 · Cited by 308
Scheithauer, W., McKendrick, J., Begbie, S., Borner, M., Burns, W. I., Burris, H. A., Cassidy, J., Jodrell, D., Koralewski, P., Levine, E. L., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg500 · Cited by 276
Self-citationAndré, T., Colin, P., Louvet, C., Gamelin, E., Bouche, O., Achille, E., Colbert, N., Boaziz, C., Piedbois, P., Tubiana-Mathieu, N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.065 · Cited by 262
Twelves, C., Boyer, M., Findlay, M., Cassidy, J., Weitzel, C., Barker, C., Osterwalder, B., Jamieson, C., & Hieke, K. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00444-5 · Cited by 158
Self-citationDu, X. L., Key, C. R., Osborne, C., Mahnken, J. D., & Goodwin, J. S. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-2-200301210-00009 · Cited by 101
Saini, A., Norman, A. R., Cunningham, D., Chau, I., Hill, M. E., Tait, D., Hickish, T., Iveson, T. J., Lofts, F. J., Jodrell, D. I., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600995 · Cited by 84
Self-citationCutsem, E. V., Dicato, M. A., Wils, J. A., Cunningham, D., Díaz‐Rubio, E., Glimelius, B. L. G., Haller, D. G., Johnston, P., Kerr, D. J., Koehne, C.-H., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00122-3 · Cited by 57
Cited by
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,285
Hashiguchi, Y., Muro, K., Saito, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., Hasegawa, K., Hotta, K., Ishida, H., Ishiguro, M., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01485-z · Cited by 1,922
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Metadata
- Authors
- Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., Carrato, A., Cassidy, J., Cervantes, A., Fagerberg, J., Georgoulias, V., Husseini, F., Jodrell, D., Koralewski, P., Kröning, H., Maroun, J., Marschner, N., McKendrick, J., Pawlicki, M., Rosso, R., Schüller, J., Seitz, J.-F., Stabuc, B., Tujakowski, J., Van Hazel, G., Zaluski, J., & Scheithauer, W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-06-30
- Volume
- 352
- Issue
- 26
- Pages
- 2696-2704
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2146161922
- Cited by
- 1,248
- References
- 21
- FWCI
- 34.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.